Diseases · Entity Annotation Prototype (beta)

18articles mentioning diseases

111disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: ccRCC ×

ccRCC

This disease is selected. Its supporting articles are shown below.

ccRCC18

Articles mentioning ccRCC

18 articles · page 2 of 2

Immuno-oncologic profiling of renal masses using multiparametric MRI: a pilot study

jitc · abstract · 2025-12-05 · 3 matching annotations

91.6%

ccRCC renal mass malignancy

…, 0.92) for overall detection of ccRCC, and mpMRI distinguished ccRCC from non-ccRCC with increased IVIM D and ADC with AUC(95%CI)=0.…

HMGA2 links morphological evolution and microenvironment dynamics to systemic therapy response in clear cell renal cell carcinoma

jitc · abstract · 2025-11-24 · 3 matching annotations

85.2%

Clear cell renal cell carcinoma (ccRCC)ccRCC

…Background Clear cell renal cell carcinoma (ccRCC) exhibits significant heterogeneity due to morphological changes…

67 Integrated spatial multiomics on xenium in situ platform reveals complex heterogeneity in clear cell renal cell carcinoma

jitc · abstract · 2025-11-04 · 3 matching annotations

85.8%

ccRCC therapy

…in and 477 RNA targets in FFPE clear cell renal cell carcinoma (ccRCC) samples. We performed integrated analysis of protein and RNA d…

Unexpected aggressiveness in VHL-associated clear cell renal cell carcinoma: insights from two patients highlighting biological heterogeneity

bmjcr · abstract · 2026-06-04 · 2 matching annotations

90.8%

ccRCC Von Hippel–Lindau renal cell carcinoma (RCC)RCC

…tion, WHO/ISUP grade 4, staged pT3a, consistent with aggressive ccRCC. Both presentations deviated from the traditionally indolent co…

107 Multi-omic assessment of blood and tissue of renal cell carcinoma patients provides a comprehensive characterization of the systemic and local immune response

jitc · abstract · 2025-11-04 · 2 matching annotations

85.5%

Clear cell renal cell carcinoma (ccRCC)ccRCC

…Background Clear cell renal cell carcinoma (ccRCC) represents a biologically heterogeneous malignancy with diverse…

Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma

jitc · abstract · 2026-03-03 · 1 matching annotations

79.8%

metastatic ccRCC mccRCC metastatic clear cell renal cell carcinoma ccRCC nivolumab MD Anderson Cancer Center ipilimumab

…uscle mass were associated with shorter PFS among patients with metastatic ccRCC treated with 1L nivolumab+ipilimumab. These findings support th…